Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group. Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Conditions Studied
Interventions
- DRUG BI 1584862
- DRUG Placebo-matching BI 1584862
Study Locations (20)
California
- Retina-Vitreous Associates Medical Group — Beverly Hills
- Global Research Management — Glendale
- Retina Associates of Southern California — Huntington Beach
- Retinal Consultants Medical Group, Inc — Modesto
- Northern California Retina Vitreous Associates MedicalGroup, Inc. — Mountain View
- Eye Research Foundation — Newport Beach
- Retina Consultants of San Diego — Poway
- Retinal Consultants Medical Group — Sacramento
- Bay Area Retina Associates - Walnut Creek — Walnut Creek
Florida
- Vitreo Retinal Associates - Gainesville — Gainesville
- MedEye Associates — Miami
- Eye Associates of Pinellas — Pinellas Park
- East Florida Eye Institute — Stuart
- Center for Retina and Macular Disease — Winter Haven
Arizona
- Associated Retina Consultants — Gilbert
- Associated Retina Consultants, Ltd. — Phoenix
- Cameron Ria, LLC — Phoenix
- Retina Macula Institute of Arizona — Scottsdale
Colorado
- Retina Specialists of Colorado Research, LLC — Denver
Connecticut
- Coastal Eye Surgeons — Greenwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06769048
The ClinicalTrials.gov registry entry for NCT06769048 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions — of which BI 1584862 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06769048 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06769048 about?
NCT06769048 is a clinical study titled "A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy". This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study ...
What is the current status of trial NCT06769048?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-31. Estimated completion is 2027-02-26.
What conditions does trial NCT06769048 study?
This clinical trial studies the following conditions: Geographic Atrophy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06769048?
The interventions under investigation include: BI 1584862 (DRUG), Placebo-matching BI 1584862 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06769048?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06769048 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.